Trial site
Songkhla
Songkhla, Hat Yai 90110, ThailandNot linked to an institution yet
- 9running trials
- 4closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Completed2 trials
- Recruiting2 trials
- Terminated2 trials
- Lead sponsor
- Novartis Pharmaceuticals13 trials
Running trials
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506· Phase 4· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error